Latanoprost/timolol fixed combination in the treatment of primary open-angle glaucoma

Latanoprost/timolol fixed combination (FCLT) provides clinically significant IOP reduction with a favorable tolerability profile in patients with glaucoma and ocular hypertension inadequately controlled on monotherapy. FCLT provides better IOP control compared to its components, while demonstrating a favorable safety and tolerability profile. FCLT as a single dose evening instillation provides better 24-hour IOP control. FCLT is associated with fewer side effects, more convenient dosing, and lower exposure to preservatives. These advantages have a positive impact on quality of life, compliance, and possibly on the future outcome of glaucoma surgery.